Fairmount-Linked Holders Of 9.99% Of Spyre Therapeutics Agree To 60-Day Lock-Up After Offering
Amendment No. 8 to a Schedule 13D reports the lock-up only; the holders did not buy shares and their position is unchanged since June.
Peter Evan Harwin and Tomas Kiselak reported 10,185,961 shares, or 9.99% of Spyre Therapeutics, in an amended Schedule 13D filed Friday. The amendment exists solely to disclose a lock-up agreement tied to Spyre's public offering, which closed October 7, 2026.
What the amendment says
Amendment No. 8 says the reporting persons signed a customary lock-up letter with Jefferies, TD Securities, Leerink Partners and Stifel, the representatives of the offering's underwriters. They agreed not to sell Spyre securities without the representatives' consent, plus other customary conditions, for 60 days after the date of the offering's final prospectus supplement.
The filing states that the reporting persons did not buy any Spyre securities or otherwise take part in the offering. It also says the number of common and Series A preferred shares they own has not changed since Amendment No. 7, filed June 23, 2026.
The cover pages list four reporting persons. Fairmount Funds Management and Fairmount Healthcare Fund II each show 9,354,200 shares, or 9.19%. Harwin and Kiselak each show 10,185,961 shares, or 9.99%, with 520,361 shares of sole voting power and 9,665,600 of shared voting power.
What the stake is made of
The group's holdings include 812,076 common shares it owns outright. They also include 9,100,160 shares issuable on conversion of 227,504 Series A preferred shares, and 228,646 shares from options that are exercisable now or within 60 days.
The conversion count is limited by a 9.99% ownership cap. The filing excludes 4,741,640 further common shares that could come from 118,541 Series A preferred shares held directly by Fund II, because they exceed that cap.
What it changes
For holders of Spyre, the practical effect is narrow: the Fairmount-linked group has committed not to sell during the lock-up window, and its reported position is the same as in June. Spyre shares closed at $85.69 at Friday's close, up 7.25%, according to market data; the filing does not tie that move to the lock-up.
The lock-up runs 60 days from the date of the final prospectus supplement for the offering, which closed October 7, 2026.
